This study is evaluating an investigational treatment for adults living with chronic kidney disease (CKD) who also have high uric acid levels.
High uric acid is common in people with CKD and may increase the risk of gout and place additional strain on the kidneys over time. Researchers want to learn whether this investigational treatment may help lower uric acid levels and support kidney health alongside standard care.
The study will assess how safe the treatment is and how well it works over a longer period of time.
You may be eligible if:
If eligible, you will take part in the study for up to 46 weeks, including screening, treatment, and a safety follow-up period. The study involves 11 clinic visits. All visits will require fasting blood tests, so participants must be available for early morning appointments. Clinic visits will take place during clinic business hours on weekdays, between 9am-5pm.
During the study, you will receive one of the study treatment options: either a combination of the investigational medicine and a registered comparator (Febuxostat), investigational medicine alone, or placebo. Participants are randomly assigned to a treatment group, and neither you nor the study team will know which treatment option you are receiving.
Throughout the study, doctors and nurses will closely monitor your uric acid levels, kidney function, and overall health through regular check-ups and testing.
Study assessments may include medical history collection, physical examinations, vital signs, blood tests, urine tests, abdominal and kidney ultrasound, pregnancy testing if applicable, and monitoring for side effects.
Before enrolling, the study doctor and clinical team will explain the study in detail, including information from previous research, potential risks and benefits, and what participation involves.
Eligible participants will receive reimbursement for study-related time and travel.